» Articles » PMID: 17762509

The Role of Neurotrophic Factors in Adult Hippocampal Neurogenesis, Antidepressant Treatments and Animal Models of Depressive-like Behavior

Overview
Journal Behav Pharmacol
Date 2007 Sep 1
PMID 17762509
Citations 275
Authors
Affiliations
Soon will be listed here.
Abstract

Major depressive disorder (MDD) is characterized by structural and neurochemical changes in limbic structures, including the hippocampus, that regulate mood and cognitive functions. Hippocampal atrophy is observed in patients with depression and this effect is blocked or reversed by antidepressant treatments. Brain-derived neurotrophic factor and other neurotrophic/growth factors are decreased in postmortem hippocampal tissue from suicide victims, which suggests that altered trophic support could contribute to the pathophysiology of MDD. Preclinical studies demonstrate that exposure to stress leads to atrophy and cell loss in the hippocampus as well as decreased expression of neurotrophic/growth factors, and that antidepressant administration reverses or blocks the effects of stress. Accumulating evidence suggests that altered neurogenesis in the adult hippocampus mediates the action of antidepressants. Chronic antidepressant administration upregulates neurogenesis in the adult hippocampus and this cellular response is required for the effects of antidepressants in certain animal models of depression. Here, we review cellular (e.g. adult neurogenesis) and behavioral studies that support the neurotrophic/neurogenic hypothesis of depression and antidepressant action. Aberrant regulation of neuronal plasticity, including neurogenesis, in the hippocampus and other limbic nuclei may result in maladaptive changes in neural networks that underlie the pathophysiology of MDD.

Citing Articles

Selective Noradrenergic Activation of BDNF Translation by Mirtazapine.

Ciraci V, Santoni L, Tongiorgi E Mol Neurobiol. 2024; .

PMID: 39557799 DOI: 10.1007/s12035-024-04619-1.


The Neurotrophin System in the Postnatal Brain-An Introduction.

von Bohlen Und Halbach O, Klausch M Biology (Basel). 2024; 13(8).

PMID: 39194496 PMC: 11352095. DOI: 10.3390/biology13080558.


Plasma Neurotrophic Factor Levels are not Associated with the Severity of Depression: Prospective Pilot Study.

Zorkina Y, Syunyakov T, Abramova O, Yunes R, Pavlichenko A, Pavlov K Consort Psychiatr. 2024; 2(4):13-22.

PMID: 39045452 PMC: 11262070. DOI: 10.17816/CP110.


Targeting GLP-1 receptors to reduce nicotine use disorder: Preclinical and clinical evidence.

Herman R, Schmidt H Physiol Behav. 2024; 281:114565.

PMID: 38663460 PMC: 11128349. DOI: 10.1016/j.physbeh.2024.114565.


Cannabinoid type 2 receptor inhibition enhances the antidepressant and proneurogenic effects of physical exercise after chronic stress.

Rodrigues R, Moreira J, Mateus J, Barateiro A, Paulo S, Vaz S Transl Psychiatry. 2024; 14(1):170.

PMID: 38555299 PMC: 10981758. DOI: 10.1038/s41398-024-02877-0.